Dengue virus serotype 1 (DENV-1) (DENV-1)

Dengue virus serotype 1 (DENV-1) is a member of the Flaviviridae family and one of four antigenically distinct serotypes responsible for dengue fever (World Health Organization, 2023). The virus features a positive-sense, single-stranded RNA genome that encodes three structural proteins (C, prM, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) (UniProt, P17763). DENV-1 is primarily transmitted by Aedes aegypti mosquitoes and is a leading cause of systemic viral disease in tropical regions (CDC, 2023). While many infections are asymptomatic, DENV-1 can cause severe manifestations such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Nature Reviews Disease Primers, 2016). Therapeutic interventions include the tetravalent vaccines Dengvaxia and Qdenga, which aim to provide balanced immunity across all serotypes (The Lancet, 2022). Additionally, novel small-molecule inhibitors like JNJ-1802 target the NS4B protein to prevent viral replication (Nature, 2021). A major hurdle in treatment is antibody-dependent enhancement (ADE), where sub-neutralizing antibodies from a DENV-1 infection may increase the severity of a subsequent infection with a different serotype (Science, 2016).

Other names

DENV-1Dengue virus 1Dengue virus type 1Wild-type DENV-1

Vaccines induce neutralizing antibodies against the envelope protein to prevent cell entry (The Lancet, 2022). Small-molecule inhibitors like JNJ-1802 target the NS4B protein to disrupt the viral replication complex (Nature, 2021). Other experimental agents target the NS5 RNA-dependent RNA polymerase or NS3 protease to inhibit viral genome synthesis and processing (Antiviral Research, 2020).